Correction:  N -(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells

Arturo Contis-Montes de Oca; Estefanía Rodarte-Valle; Martha Cecilia Rosales-Hernández; Edgar Abarca-Rojano; Saúl Rojas-Hernández; Manuel Jonathan Fragoso-Vázquez; Jessica Elena Mendieta-Wejebe; Ana María Correa-Basurto; Ismael Vázquez-Moctezuma; José Correa-Basurto

doi:10.18632/oncotarget.26672

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells

PDF | How to cite

Oncotarget. 2019; 10:1225-1225. https://doi.org/10.18632/oncotarget.26672

Metrics: PDF 1330 views | ?

Arturo Contis-Montes de Oca^1,*, Estefanía Rodarte-Valle^2,*, Martha Cecilia Rosales- Hernández², Edgar Abarca-Rojano³, Saúl Rojas-Hernández¹, Manuel Jonathan Fragoso-Vázquez⁴, Jessica Elena Mendieta-Wejebe², Ana María Correa-Basurto², Ismael Vázquez-Moctezuma² and José Correa-Basurto^2,5

¹ Laboratorio de Inmunobiología Molecular y Celular, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México
² Laboratorio de Biofísica y Biocatálisis, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México
³ Laboratorio de Respiración Celular, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México
⁴ Departamento de Química Orgánica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México
⁵ Laboratorio de Modelado Molecular y Bioinformática y Diseño de Fármacos, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México
^* These authors contributed equally to this work

Published: February 05, 2019

This article has been corrected: The correct author list is given below:

Original article: Oncotarget. 2018; 9:33368-33381. DOI: https://doi.org/10.18632/oncotarget.26077.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26672

Publication Alerts

Corrections:

Correction: N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells